Trial Profile
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Integrase inhibitors; Maraviroc; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms TRULIGHT
- 16 Mar 2021 Primary endpoint has been met. (Viral Load at 48 weeks), as per Results published in the Journal of Antimicrobial Chemotherapy
- 16 Mar 2021 Results published in the Journal of Antimicrobial Chemotherapy
- 11 Jul 2019 Results of pooled analysis of data from MONCAY and TRULIGHT trials assessing proportion of participants who had no detectable HIV in genital fluids were published in the Clinical Infectious Diseases.